• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Post-Approval Studies (PAS) Database

  • Print
  • Share
  • E-mail
-

The FDA has the authority to require sponsors to perform a post-approval study (or studies) at the time of approval of a premarket approval (PMA), humanitarian device exemption (HDE), or product development protocol (PDP) application. Post-approval studies can provide patients, health care professionals, the device industry, the FDA and other stakeholders information on the continued safety and effectiveness (or continued probable benefit, in the case of an HDE) of approved medical devices. This database allows you to search Post-Approval Study information by applicant or device information.

Learn more...


           

MiniMed 780G New Enrollment Study


Suggest Enhancement / Report Issue | export reports to excelExport to Excel
General
Study Status Delayed
Application Number /
Requirement Number
P160017 S091/ PAS001
Date Original Protocol Accepted 06/15/2023
Date Current Protocol Accepted 10/10/2024
Study Name MiniMed 780G New Enrollment Study
Device Name MiniMed 780G System
Clinical Trial Number(s) NCT03959423  
General Study Protocol Parameters
Study Design Active Surveillance
Data Source New Data Collection
Comparison Group No Control
Analysis Type Descriptive
Study Population Child: 2-12 yrs, Adolescent: 13-18 yrs, Transit. Adolescent B (as adults) : 18-21 yrs, Adult: >21
Interim or Final Data Summary
Interim Results Safety Results:
The sponsor reported that there were 2 severe hypoglycemia, diabetic ketoacidosis (DKA), and 2 hospitalization events related to
the use of the MiniMed 780G system collected via biweekly surveys and/or Technical Support during the analysis period. A total of 684
adverse events (AE) were reported through surveys or Technical Support during the analysis period, including two deaths, 12 occurrence of inflammation and blister formation affecting the skin, 437 occurrences of hematoma/hemorrhage/bleeding, 94 hypoglycemia events, and one absence seizure event.

Effectiveness Results:
Participants demonstrated time in the target range (TIR) of 80 +/-10.2% with use of the pump system 99.9 +/-0.7% and SmartGuard use 92.4 +/-13.5% of time 0-3 months after completing the first biweekly survey (N=1,863). Participants reported a mean HbA1c of 6.8 +/-0.7% 0-3 months after completing the first survey.
Actual Number of Patients Enrolled 1,995
Actual Number of Sites Enrolled N/A
Patient Follow-up Rate The sponsor reported that the biweekly survey return rate is 92.98%. The sponsor did not provide return rates for each age cohort or report whether any participants have been lost to follow-up.


MiniMed 780G New Enrollment Study Reporting Schedule

Reporting Schedule
Report
Date Due
FDA Receipt
Date
Applicant's Reporting Status
6 month report 10/20/2023 10/19/2023 On Time
1 year report 04/20/2024 04/19/2024 On Time
18 month report 10/19/2024 10/18/2024 On Time
2 year report 04/20/2025    
3 year report 04/20/2026    
final report 07/23/2026    


Contact Us

Mandated Studies Program
Food and Drug Administration
10903 New Hampshire Ave.
Silver Spring, MD 20993-0002
Email: MandatedStudiesPrograms@fda.hhs.gov

Additional Resources

-
-